ALS treatment
adapted for
the real world

Teglutik® is aligned to the QIPP programme

There is good evidence that focusing on delivering high quality care, prevention and early intervention can improve efficiency and save NHS resources.1

TEGLUTIK®
DELIVERS
HIGH-QUALITY
CARE:*
  • Teglutik® demonstrated bioequivalent efficacy (total exposure) to riluzole tablets2
  • Teglutik’s® unique formulation minimises the distress of disease progression by enabling patients to take the same medication throughout their journey3
  • Riluzole is generally well tolerated with little need for dose reductions2
*High-quality care defined by NHS QIPP introduction for clinicians as clinical effectiveness, safety and patient experience
TEGLUTIK® COULD
HELP PREVENT
HOSPITAL ADMISSIONS
FOR PATIENTS
WITH ALS:
  • With its nectar-like consistency, Teglutik® may reduce aspiration pneumonia – the leading cause of hospital admissions in ALS4-6
USED EARLY,
TEGLUTIK® COULD
OFFER PATIENTS
SIGNIFICANTLY
MORE TIME THAN
CRUSHED TABLETS:
  • Riluzole has the greatest effect on slowing disease progression when used in the early stages of disease7
  • Patients need to receive the recommended 100 mg dose to benefit from treatment8
  • Crushing a solid dose formulation means patients achieve sub-optimal dose and effect from their treatment4,8,9
  • Teglutik® ensures your patients receive the full 100 mg dose by enclosing fixed dose riluzole in a liquid-suspension formulation4
Welcome
to Teglutik®

Teglutik® is the first oral liquid suspension formulation of riluzole, the only licensed treatment for patients with amyotrophic lateral sclerosis (ALS), the most common type of motor neuron disease (MND).

This site provides information on Teglutik® and ALS for UK-based healthcare professionals and patients. Please select from the buttons below to tailor the content to your needs:

I am a UK healthcare professional
I am not a healthcare professional

For additional information about MND you can visit the Motor Neurone Disease Association website. The Motor Neurone Disease Association is the only national charity in England, Wales and Northern Ireland focused on MND care, research and campaigning

http://www.mndassociation.org/